Medicine for treating malignant pleural effusion with syndrome of phlegm-dampness due to spleen deficiency

Abstract

The invention provides a medicine for treating malignant pleural effusion with syndrome of phlegm-dampness due to spleen deficiency. The medicine consists of the following medicinal raw materials: rheum officinale, semen lepidii, radix curcumae, cassia twig, bigflower cape jasmine fruit, pseudobulbus cremastrae seu pleiones, selfheal, codonopsis pilosula, dried ginger, schisandra chinensis, hemarthria sibirica, oriental dodartia herb, platycodon grandiflorum, radix angelicae pubescentis, herba ephedra, radix liriopes, fructus arctii, bighead atractylodes rhizome, radix scrophulariae, rhizoma acori graminei and liquorice root. The medicine, in combination with pleural infusion chemotherapy, provides an effective means for treating malignant pleural effusion, so as to relieve the reoccurrence speed of lung cancer with pleural effusion and to enhance a curative effect; in addition, in combination with traditional Chinese medicines, the medicine can relieve toxic and side effects caused by the chemotherapy and consolidate the curative effect; and meanwhile, the medicine can improve life quality and relieve clinical symptoms of a patient, and can give consideration to both the whole and the part of the patient, so as to achieve purposes of strengthening body resistance and eliminating evil.

Description

technical field

[0001] The invention relates to the technical field of traditional Chinese medicine, in particular to a medicine for treating malignant pleural effusion of spleen deficiency and phlegm-dampness type. Background technique

[0002] Malignant pleural effusion refers to pleural effusion caused by malignant tumor involving the pleura or primary pleural tumor. It is one of the common complications of malignant tumors in the late stage, and the incidence rate accounts for about 25% of pleural effusions. Malignant tumors that cause malignant pleural effusions include lung cancer, breast cancer, and lymphoma. Clinically, it can cause symptoms such as chest pain and dyspnea, and even respiratory failure, which seriously affects the quality of life of patients and shortens the survival time of patients. Some studies have shown that the survival time is generally less than 6 months. The rapid growth of malignant pleural effusion can cause compressive atelectasis and res...